MedCity News

JANUARY 15, 2024

Morgan Healthcare Conference, CEO Joshua Brumm said Dyne’s existing cash combined with the new capital is expected to last through 2025—well beyond the next key milestones for both therapeutic candidates. Dyne Therapeutics recently reported encouraging Phase 1/2 clinical data in myotonic dystrophy type 1 and Duchenne muscular dystrophy.

Medicine 118

Medicine Healthcare Healthcare Biopharma 118

MedCity News

OCTOBER 9, 2024

and European regulatory submissions for the drug are now planned for early 2025. On the heels of Phase 3 data showing muscle improvement in the rare neuromuscular disease spinal muscular atrophy, Scholar Rock raised $300 million in a stock offering.

Biopharma 115

Biopharma Pharma 115

Pharmaceutical Technology

SEPTEMBER 5, 2022

Until 2025, we have strong growth ahead of us, but we also believe we can continue to grow very strongly post-2025 and it’s all about innovation in the pipeline.”. On 23 August, at a Reuters Newsmakers online forum, Soriot announced his interest in increasing AstraZeneca’s portfolio of bolt-on acquisitions leading up to 2025.

FDA 114

FDA Pharmaceutical Biopharma Pharma 114

European Pharmaceutical Review

SEPTEMBER 26, 2022

The €60 million expansion will open 70 new jobs in sterile manufacturing, quality control and engineering in 2025. Earlier this year, AbbVie was named Best Workplace for Women and ‘Biopharma Company of the Year’ at the latest Irish Pharma Industry Awards. AbbVie announces Michael Severino, M.D.

Manufacturing 98

Manufacturing Pharmaceutical manufacturing Biopharma Engineering 98

Clarivate

OCTOBER 31, 2023

These years witnessed significant troughs in pharma financing, a drop in the capital markets, and an IPO window that remained firmly shut. Big pharma is still keen to access good technology, science, and assets, in many cases to plug a patent-expiry-shaped hole in their coffers. In short, the biotech bubble had burst. Pfizer’s $11.6

Pharma 52

Pharma Biopharma Marketing Healthcare 52

MedCity News

MARCH 11, 2024

Boehringer Ingelheim can exercise its option on the small molecule following a Phase 1 test expected to yield data in 2025. Sosei Heptares’ schizophrenia drug candidate addresses a novel, difficult-to-drug target for neurological disorders.

Biopharma 75

Biopharma Pharma 75

Clarivate

JANUARY 23, 2024

R&D spend is steadily growing and is expected to reach approximately $200 billion by 2025. To learn more about how Clarivate and CMR International help pharmas future-proof their portfolios, please visit us here. The post Pharma R&D productivity dips, but efficiency gains give hope appeared first on Clarivate.

Pharma 52

Pharma Sales Consulting Pharmaceutical 52

European Pharmaceutical Review

APRIL 30, 2024

What are the top three trends that you are seeing in the biopharma manufacturing space? Let’s talk about continuous biopharma manufacturing. Speaking of your biopharma clients, what are you hearing about their main priorities? I see the market picking back up towards the end of 2024 or early 2025.

Manufacturing 97

Manufacturing Food and Drug Administration Biopharma Marketing 97

PM360

AUGUST 26, 2024

Fortune 500s or Start-Ups; what are the opportunities and challenges for top school business graduates to consider for the Healthcare/Pharma/Biotech vertical? A: (Galeota) MIT Sloan’s and all MIT students should consider the tremendous career opportunities that the Healthcare/Pharma/Biotech vertical offers.

Distribution 52

Distribution Biopharma Healthcare Healthcare 52

Clarivate

APRIL 24, 2023

billion venture with private equity firm Welsh, Carson, Anderson & Stowe to develop 100 new senior-focused clinics between 2023 and 2025. Less than a year after acquiring Kindred at Home in and rebranding it CenterWell Home Health, Humana announced in May 2022 a $1.2 Key acquisitions by U.S.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

Clarivate

MAY 13, 2024

After staying relatively flat for several years, enrollment growth took off in 2021 after an expansion in federal subsidies for silver-level plans passed in the American Rescue Plan and was then renewed through 2025 in the Inflation Reduction Act.

Insurance 52

Insurance Marketing Healthcare Healthcare 52

Clarivate

OCTOBER 10, 2022

Nevertheless, the anticipated entry of pertuzumab biosimilars in 2025 and the reimbursement status for both brands on NRDL in this patient segment is likely to influence first-line uptake of pyrotinib in Mainland China.

Marketing 52

Marketing Safety Patients Competition 52

Pharmaceutical Technology

APRIL 24, 2023

Meanwhile, the Indian biologics market is expected to grow to $12 billion by 2025, with a compound annual growth rate (CAGR) of 22%. Free Whitepaper Choosing the ‘right’ CRO/CDMO in Biopharma: What has changed? Biopharma outsourcing has rapidly developed.

Manufacturing 52

Manufacturing Food and Drug Administration Biopharma Sales 52

Clarivate

AUGUST 20, 2024

In 2025, CMS will select another 15 Part D drugs for negotiations that will take effect in 2027. Pharmas may choose to accept these discounts as a standard business cost or revise their strategies to mitigate the risk of being selected for price negotiations. That compares to the $240.4 billion spent on all Part B drugs that same year.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

Clarivate

OCTOBER 17, 2024

However, recommendations from the Heritage Foundation’s Project 2025 could influence policymaking under a Trump administration. The immediate issue for whoever wins will be expanded subsidies extended by the Inflation Reduction Act, which are set to expire at the end of 2025. Extending them would require Congressional action.

Healthcare 52

Healthcare Healthcare Government Insurance 52